Tagged with OP

Switzerland The president of BD Europe analyses current trends and challenges in European healthcare and highlights how BD is positioning itself as a solutions provider and partner to cope with this new environment. BD acquired CareFusion in 2015 and September 30th 2016 marked the end of BD’s first full fiscal year of…

Taiwan Freddie Höglund, CEO of the European Chamber of Commerce Taiwan (ECCT), and Mike Exton, Managing Director of Novartis Taiwan and Co-Chair of the Pharmaceutical Committee of the ECCT, document the main issues at stake for the international pharmaceutical companies implanted in Taiwan, while providing us with a broader overview of…

Taiwan Yung Fa Chen, ScinoPharm’s President and CEO, documents his strategy to drive the Taiwan-based global success story to new heights, having established itself as an indisputable leader in the API field, providing its international partners with complex, difficult-to-make products. Yung Fa Chen notably explains how he wants to further leverage…

Europe Europe accounts for 22.2 percent of global pharma sales; more than Africa, Asia, Australasia, and Latin America combined, but less than half of North America. The biopharmaceutical industry is a key contributor to the European economy in terms of both trade surplus and employment; especially highly-skilled R&D jobs. Germany is…

Asia 2016 was a year of great activity for the pharma industry, with economic uncertainties, seismic political shifts in the UK and US, and cost-containment measures in several countries. Consequently, PharmaBoardroom surveyed over 400 of its executive readership over four continents to get a sense of their optimism for the industry in 2017.…

Mexico Paulo de Resende, CEO of Laboratorios Grin-Lupin in Mexico, describes the current state of the Mexican pharmaceutical market and explains how the acquisition of Laboratorios Grin will help increase Lupin’s footprint in Latin America by bringing more expertise and R&D resources. Could you please introduce yourself to our international audience…

Taiwan Ten years after its creation in 2005, InnoPharmax was ranked seventh fastest growing technology company in Taiwan in Deloitte’s “Technology Fast 500 Asia Pacific” annual ranking. CS Hsu, founder and president of InnoPharmax, introduces the company’s most fundamental asset – OralPAS®, its unique technology platform, and documents the promising development…

Mexico José Luis Hernández, general manager at Kedrion Mexico, explains the strategy followed by the affiliate in Mexico to obtain success during the past eight years and showcases the added value of plasma-derivate solutions both for patients and government. What are the primary activities and operations of Kedrion in Mexico? Kedrion…

Switzerland Niche generics manufacturer Rivopharm was nearly bankrupt when acquired by current president and CEO Piero Poli in 2005; he explains the changes and strategy he put in place to drive the company to over 5x growth in the last 12 years while successfully bringing the first generics of several niche…

Switzerland The CEO of Max Zeller, a Swiss Phytopharmaceutical company, highlights the immense benefits his products have and furthermore discusses the company’s internationalization strategy. Mr Boonen, you joined Max Zeller in June 1999 and have spent almost all your professional career here. How have you seen the company evolve over time…

Switzerland Santen’s Head of EMEA explains why the company established their new regional headquarters in Geneva, Switzerland and highlights the three key strategic pillars on which he bases the growth strategy for the region.   The immense talent present here contributes to the strategic value of the EMEA region, which we…

Ireland Ronan Quinn, CEO of Ardmac, an international provider of high-tech cleanroom facilities to the life sciences sector, tells us the inspiring story of Ardmac’s continued growth through the recent economic recession, the second-generation cleanroom technologies they are bringing to the market, and his positive outlook for Ardmac in the next…